It is expected that the production approval of levetiracetam, a class 3.1 antiepileptic drug of xinlitai, will be obtained this month
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on the website of CFDA on June 9, the raw materials and tablets of 3.1 chemical drug levetiracetam declared by xinlitai for production have become "approved pending certification" If there is no accident, the company is expected to obtain production approval this month to achieve the first domestic imitation Levetiracetam is mainly used for the treatment of localized and secondary systemic epilepsy, and currently only the original research drug is on sale in China Xinlitai applied for clinical approval of the product in April 2002 and production in February 2011 "The product is an epileptic drug developed by the company in the early years After being approved, it will enrich the product line of the company, but it will not change the company's development strategy dominated by cardiovascular and cerebrovascular products," the company said Xinlitai is mainly engaged in the research, development and sales of cardiovascular drugs, with nearly 1000 academic teams in the field of cardiovascular medicine Its main products include clopidogrel, bivarutin, alisartan ester, coronary stent and other products Among them, about 40% of the company's revenue, clopidogrel tablets, under the impact of competitors' low prices, have successively lost the base drug market in some provinces and cities.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
